IXHL Incannex Healthcare Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1873875 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY69.0%
TTM EPS YoY97.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-20.7%
ROA-19.9%
ROIC (approx.)-1,944.8%
Asset turnover—
Leverage & solvency
Liabilities / assets6.0%
Debt / equity0.00x
Current ratio67.79x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.21x
Accruals ratio-15.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q12026-09-30 | 2026Q4*2026-06-30 | 2026Q32026-03-31 | 2026Q22025-12-31 | 2026Q12025-09-30 | 2025Q4*2025-06-30 | 2025Q3*2025-03-31 | 2025Q22024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | — | — | — | $0 | $0 | $0 | $12,000 |
| R&D expense | $1.12M | $1.49M | $321,000 | $2.28M | $1.12M | $3.70M | $2.73M | $1.41M |
| SG&A expense | $2.31M | $3.70M | $3.73M | $4.71M | $5.67M | $3.83M | $2.27M | $3.60M |
| Operating income | -$3.44M | -$5.19M | -$4.05M | -$7.00M | -$6.79M | -$7.53M | -$5.00M | -$5.00M |
| Interest expense | — | — | — | -$5,000 | -$5,000 | $0 | $132,000 | -$28,000 |
| Pretax income | -$1.94M | -$2.49M | -$3.88M | -$6.52M | -$6.41M | -$31.60M | -$3.97M | -$5.89M |
| Income tax | $0 | — | — | — | $0 | — | — | — |
| Net income | -$1.94M | -$2.49M | -$3.88M | -$6.52M | -$6.41M | -$31.60M | -$3.97M | -$5.89M |
| EBITDA | -$3.43M | -$5.14M | -$3.98M | -$6.94M | -$6.73M | -$7.47M | -$5.01M | -$4.80M |
| EPS (basic) | -0.15 | — | -0.35 | -0.02 | -0.62 | — | -6.19 | -0.33 |
| EPS (diluted) | -0.15 | — | -0.35 | -0.02 | -0.62 | — | -6.19 | -0.33 |
| Weighted avg. shares (diluted) | 12.54M | — | 12.35M | 349.46M | 10.34M | — | 654,418 | 17.62M |
| Balance sheet | ||||||||
| Cash & equivalents | $68.27M | $67.71M | $74.45M | $68.90M | $73.28M | $15.04M | $6.71M | $2.10M |
| Current assets | $70.23M | $72.83M | $80.09M | $74.68M | $78.30M | $19.96M | $15.63M | $10.50M |
| PP&E, net | $2,000 | $4,000 | $47,000 | $108,000 | $168,000 | $227,000 | $277,000 | $273,000 |
| Total assets | $70.39M | $72.98M | $80.28M | $75.01M | $78.72M | $20.45M | $16.20M | $11.11M |
| Current liabilities | $1.04M | $1.49M | $1.93M | $1.55M | $1.65M | $6.98M | $7.37M | $5.84M |
| Short-term debt | — | — | — | — | — | — | $1.40M | $1.38M |
| Long-term debt | — | — | — | — | — | — | — | $2.38M |
| Total debt | — | — | — | — | — | — | — | $3.77M |
| Total liabilities | $4.26M | $5.61M | $5.05M | $1.60M | $1.71M | $7.06M | $8.79M | $10.14M |
| Shareholders' equity | $66.14M | $67.37M | $75.23M | $73.41M | $77.01M | $13.39M | $7.40M | $964,000 |
| Net debt | — | — | — | — | — | — | — | $1.67M |
| Shares outstanding | 12.54M | 12.54M | 13.68M | 359.22M | 347.71M | 6.48M | 17.79M | 17.79M |
| Cash flow statement | ||||||||
| Operating cash flow | $521,000 | $3.37M | -$2.46M | -$4.62M | -$9.16M | -$1.48M | -$3.16M | -$5.68M |
| Capital expenditure | $0 | -$1,000 | $5,000 | $4,000 | $2,000 | $0 | $0 | — |
| Free cash flow | $521,000 | $3.38M | -$2.46M | -$4.63M | -$9.16M | -$1.48M | -$3.16M | — |
| Investing cash flow | -$54,000 | -$30,000 | -$18,000 | -$4,000 | -$42,000 | $0 | $0 | — |
| Financing cash flow | $0 | -$6.91M | $4.71M | $927,000 | $67.18M | $9.60M | $7.74M | $4.10M |
| Depreciation & amortization | $2,000 | $50,000 | $65,000 | $59,000 | $66,000 | $61,000 | -$5,000 | $200,000 |
| Stock-based compensation | $312,000 | $1.19M | -$1.47M | -$2.28M | $2.63M | $1.30M | -$416,000 | -$435,000 |
| Share buybacks | — | $7.08M | $1.14M | — | — | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 16 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.